Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
about
Pharmacology of proton pump inhibitorsAcid suppression and the risk of Clostridium difficile infectionAbsence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.Esophageal cell proliferation in gastroesophageal reflux disease: clinical-morphological data before and after pantoprazolePharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.Symptomatic reflux disease: the present, the past and the future.Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.Quantification of dental erosions in patients with GERD using optical coherence tomography before and after double-blind, randomized treatment with esomeprazole or placebo.Republished: symptomatic reflux disease: the present, the past and the future.The value of branded proton pump inhibitors: formulary considerations.Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mgRelationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux diseaseRandomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux diseaseEvaluation of regional and whole gut motility using the wireless motility capsule: relevance in clinical practice.The Indications, Applications, and Risks of Proton Pump InhibitorsRisk of community-acquired pneumonia in patients with a diagnosis of pernicious anemia: a population-based retrospective cohort study.Treatment of uncomplicated reflux diseaseTherapeutic options in the treatment of nighttime gastroesophageal reflux.Acid suppression therapy: where do we go from here?Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis.A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori InfectionComparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial.Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitorComparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: a randomized, double-blind, controlled studyClinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients.Use of proton pump inhibitors and subsequent risk of celiac diseaseComparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease.Laryngopharyngeal reflux disease in children.Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparisonConcurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.The Current Use of Proton-Pump Inhibitor Therapy in Clinical GI Practice.Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionEsomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis.Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation.
P2860
Q24634771-12ED2336-AB9B-4DC5-A9A2-5064A919BB44Q26823599-2A8D5F61-2A05-4EF9-AE24-75F3BD3CF082Q33338273-2594DDD0-5F7D-48B7-B080-C49956A8C575Q33413173-27B0329D-9C6C-418B-B509-F2EEF8EEAA65Q33698543-72E68214-C276-459D-A507-77A6AC147CC1Q33834731-790BCF00-5E8C-49B2-ADEC-46CC5DCC42E5Q33855564-486FD63E-3DBE-4890-8315-08AD8D2DD156Q34206222-F4338D45-9B52-4F48-9C59-51ECF65B2AA8Q35048270-4178E924-1B8D-4314-A58D-98F9C1FF67B0Q35209935-A30619AA-0333-4C3E-9289-2163F040DDC6Q35304679-8260F9E2-364B-4F98-B62B-5F814D571CCBQ35987371-16D4F48A-8BE9-4396-BCAA-EDCF605C179EQ35990355-2A3CF93A-FB65-41BF-AD13-61732131C3B9Q36072682-3077C29C-2E0F-43E2-A651-010CE151E157Q36091187-7B0820BA-8817-4773-8671-C2BC18E704F7Q36101677-D5F125D4-0E43-486E-B0C5-DB76F7DE24DFQ36204260-B04D0E0B-B867-4979-B3FB-8BBAFB2612C5Q36327508-9DC672ED-A165-4BC5-917C-89EE186B6D0FQ36478082-1D710A45-C10A-42A2-9E9B-946AD8FA1040Q36542670-CF23E89A-21A3-4238-8EDE-A4BF2A3CB397Q36753973-2D218E48-FFC4-4CB4-B2B4-2560AF0F45BFQ36822599-CA8CA23A-1377-4AD2-9542-FEC0D60464D2Q36932316-CC1728E9-1161-4030-BED9-2EA3ED731745Q37018462-91008546-2DD7-4183-8611-4CAAAD64B98BQ37160360-D8241C11-A5BB-46D8-85BE-30B0CC5ED283Q37187264-537D6C45-18DD-404A-838F-F2C9AF232DE2Q37237706-13A64A5A-1B51-4A2A-9896-36320D98CB0EQ37561598-220EF4AA-0CE0-4188-B980-6BACEAE2B7E9Q37625863-64575AD3-ABC3-43A0-9036-2914EA8EEC6BQ37708037-9483FE0E-EA23-4BB9-815A-5565C594A078Q37740015-03CAE6A1-64A9-4C9B-B7FE-65D5A8C1FBF9Q38125748-31D07F83-9166-4156-8172-5D49D7D122E5Q39014361-B7B92087-9312-41E3-9D31-80D78DA3E449Q41404243-9D8373E7-DDA2-48FC-9E20-FD58C36BB08BQ41634946-E2B40971-0028-45E8-9B55-A97BEE436CE1Q41976827-BDE0D472-0377-4138-8A3D-46D0BA2B6469Q42283418-6D014772-6DBF-4EA5-869D-4524DB79D935Q42371575-91D027EA-A124-482D-9088-2ADB277F2A65Q45248793-FE42E5FB-3147-4D7B-B4DF-88FBDF24F932Q47132139-573D19D2-3BFB-4D12-A555-39CD9A648125
P2860
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Gastric acid control with esom ...... e: a five-way crossover study.
@ast
Gastric acid control with esom ...... e: a five-way crossover study.
@en
type
label
Gastric acid control with esom ...... e: a five-way crossover study.
@ast
Gastric acid control with esom ...... e: a five-way crossover study.
@en
prefLabel
Gastric acid control with esom ...... e: a five-way crossover study.
@ast
Gastric acid control with esom ...... e: a five-way crossover study.
@en
P2093
P1476
Gastric acid control with esom ...... e: a five-way crossover study.
@en
P2093
Mark Sostek
Philip Miner
Philip O Katz
Yusong Chen
P304
P356
10.1016/J.AMJGASTROENTEROL.2003.09.053
P407
P577
2003-12-01T00:00:00Z